Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).

by Susana Cedrés, Santiago Ponce-Aix, Jon Zugazagoitia, Irene Sansano, Ana Enguita, Alejandro Navarro-Mendivil, Alex Martinez-Marti, Pablo Martinez, Enriqueta Felip
Published 2015-01-01

MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma

by Irene Ferrer, Álvaro Quintanal-Villalonga, Sonia Molina-Pinelo, Jose Manuel Garcia-Heredia, Marco Perez, Rocío Suárez, Santiago Ponce-Aix, Luis Paz-Ares, Amancio Carnero
Published 2018-08-01

361 A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma – 12 month analysis of biomarkers...

by Magnus Jaderberg, Victor Levitsky, Luis Paz-Ares, Lukasz Kuryk, Nicolas Isambert, Susana Cedres, Xavier Serres, Charles Ricordel, Santiago Ponce Aix, Anne-Sophie Moller, Sylvia Vetrhus
Published 2020-11-01

nab-Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+)

by Daniel Morgensztern, Manuel Cobo Dols, Santiago Ponce Aix, Pieter E. Postmus, Jaafar Bennouna, Jürgen R. Fischer, Oscar Juan-Vidal, David J. Stewart, Andrea Ardizzoni, Rafia Bhore, Marianne Wolfsteiner, Martin Reck, Denis Talbot, Ramaswamy Govindan, Teng Jin Ong
Published 2021-02-01

Tumor mutational burden assessment in non-small-cell lung cancer samples: results from the TMB2 harmonization project comparing three NGS panels

by Fernando López-Ríos, Luis Paz-Ares, Pilar Garrido, Eva M Garrido-Martin, Jose Palacios, Elena Sanchez, Ana Belén Enguita, Javier Ramos-Paradas, Susana Hernández-Prieto, David Lora, Aranzazu Rosado, Tamara Caniego-Casas, Nuria Carrizo, María Teresa Muñoz-Jimenez, Borja Rodriguez, Urbicio Perez-Gonzalez, David Gómez-Sánchez, Irene Ferrer, Santiago Ponce Aix, Ángel Nuñez Buiza
Published 2021-05-01